{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T01:12:57Z","timestamp":1787447577733,"version":"build-2736575974"},"reference-count":47,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T00:00:00Z","timestamp":1781308800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Italian Ministry of Health with Ricerca Corrente and 5\u2009\u00d7\u20091000"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hand\u2013foot syndrome (HFS) is a complication of many anticancer therapies and negatively affects patients\u2019 quality of life (QoL). Currently, little data are available on using non-pharmacological skin products as standard therapy for HFS.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>This study aims to investigate whether a specific set of cosmetic products is effective for managing HFS skin side effects in cancer patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>This single-arm study involved 53 cancer patients with grade 1 HFS undergoing chemotherapy, targeted, or hormonal treatments at the European Institute of Oncology. The study included a baseline visit and a follow-up visit 45\u2009days later. All enrolled patients were prescribed a set of four cosmetic products for skin treatment. Patients underwent instrumental measurement to evaluate skin hydration and erythema, while their QoL was assessed using the Skindex-16 self-questionnaire. Additionally, physicians clinically evaluated the HFS severity, using the CTCAE (Common Terminology Criteria for Adverse Events) scale and by comparing patient photographs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>No patients worsened. After 45\u2009days, the application of the cosmetic set increased skin hydration by 33% (P\u2009&amp;lt;\u2009.0001), while skin erythema decreased by 82.9% (P\u2009&amp;lt;\u2009.0001). Patients also showed a significantly lower mean Skindex-16 score at 45\u2009days (\u221235.5%, P\u2009&amp;lt;\u2009.0001) compared to baseline. These findings were associated with clinical improvement in HFS-related skin symptoms in 58.5% of patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>These results show that a set of cosmetic products specific for cancer skin care can effectively manage HFS-related symptoms, resulting in improved QoL for patients, regardless of the anticancer treatment received.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyag233","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T11:49:55Z","timestamp":1781178595000},"source":"Crossref","is-referenced-by-count":1,"title":["Evaluation of the efficacy of topical cosmetic products in patients with hand-and-foot syndrome undergoing oncological treatments"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-7239-8807","authenticated-orcid":false,"given":"Antonia","family":"Martuscelli","sequence":"first","affiliation":[{"name":"Oncology Aesthetics Center, IEO Istituto Europeo di Oncologia IRCCS , 20141 Milan,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8231-2814","authenticated-orcid":false,"given":"Giulio","family":"Tosti","sequence":"additional","affiliation":[{"name":"Dermato-Oncology Unit, IEO European Institute of Oncology IRCCS , 20141 Milan,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5309-4704","authenticated-orcid":false,"given":"Patrick","family":"Maisonneuve","sequence":"additional","affiliation":[{"name":"Division of Epidemiology and Biostatistics, IEO European Institute of Oncology IRCCS , 20141 Milan,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina","family":"Redaelli","sequence":"additional","affiliation":[{"name":"Oncology Aesthetics Center, IEO Istituto Europeo di Oncologia IRCCS , 20141 Milan,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirella","family":"Indino","sequence":"additional","affiliation":[{"name":"IEO Istituto Europeo di Oncologia IRCCS , 20141 Milan,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Cereda","sequence":"additional","affiliation":[{"name":"IEO Istituto Europeo di Oncologia IRCCS , 20141 Milan,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1781-2518","authenticated-orcid":false,"given":"Giuseppe","family":"Curigliano","sequence":"additional","affiliation":[{"name":"Department of Oncology and Hemato-Oncology, University of Milano La Statale , 20122 Milan,","place":["Italy"]},{"name":"Division of Early Drug Development for Innovative Therapies, IEO European Institute of Oncology IRCCS , 20141 Milan,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2976-2346","authenticated-orcid":false,"given":"Ida","family":"Minchella","sequence":"additional","affiliation":[{"name":"Division of Early Drug Development for Innovative Therapies, IEO European Institute of Oncology IRCCS , 20141 Milan,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,6,12]]},"reference":[{"key":"2026071005213761900_oyag233-B1","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1111\/ijd.16361","article-title":"Evaluation of chemotherapy-induced cutaneous side effects in cancer patients","volume":"61","author":"Saadet","year":"2022","journal-title":"Int J Dermatol"},{"key":"2026071005213761900_oyag233-B2","doi-asserted-by":"publisher","first-page":"41","DOI":"10.4103\/ijd.IJD_65_17","article-title":"Cutaneous adverse reactions of chemotherapy in cancer patients: a clinicoepidemiological study","volume":"63","author":"Biswal","year":"2018","journal-title":"Indian J Dermatol"},{"key":"2026071005213761900_oyag233-B3","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1016\/j.jaad.2014.12.010","article-title":"Incidence and risk of xerosis with targeted anticancer therapies","volume":"72","author":"Valentine","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"2026071005213761900_oyag233-B4","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.jaad.2014.07.032","article-title":"Cutaneous adverse effects of targeted therapies: part I: inhibitors of the cellular membrane","volume":"72","author":"Macdonald","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"2026071005213761900_oyag233-B5","doi-asserted-by":"publisher","first-page":"734249","DOI":"10.1155\/2014\/734249","article-title":"Epidermal growth factor receptor inhibitors: a review of cutaneous adverse events and management","volume":"2014","author":"Chanprapaph","year":"2014","journal-title":"Dermatol Res Pract"},{"key":"2026071005213761900_oyag233-B6","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1177\/1078155220970621","article-title":"Dermatological side effects of immunotherapy drugs and targeted cancer therapies: importance of dermatology and oncology collaboration","volume":"27","author":"\u00c7elik","year":"2021","journal-title":"J Oncol Pharm Pract"},{"key":"2026071005213761900_oyag233-B7","author":"Common Terminology Criteria for Adverse Events (CTCAE) v5.0","year":"2017"},{"key":"2026071005213761900_oyag233-B8","doi-asserted-by":"publisher","first-page":"208","DOI":"10.4103\/ijp.ijp_175_21","article-title":"Hand\u2013foot syndrome induced by chemotherapy drug: case series study and literature review","volume":"54","author":"Zaiem","year":"2022","journal-title":"Indian J Pharmacol"},{"key":"2026071005213761900_oyag233-B9","doi-asserted-by":"publisher","first-page":"5943","DOI":"10.1007\/s00520-020-05443-8","article-title":"Real-world data of the association between quality of life using the EuroQol 5 dimension 5 level utility value and adverse events for outpatient cancer chemotherapy","volume":"28","author":"Hirose","year":"2020","journal-title":"Support Care Cancer"},{"key":"2026071005213761900_oyag233-B10","first-page":"e61-5","article-title":"The effect of hand-foot skin reaction associated with the multikinase inhibitors sorafenib and sunitinib on health-related quality of life","volume":"11","author":"Nardone","year":"2012","journal-title":"J Drugs Dermatol"},{"key":"2026071005213761900_oyag233-B11","doi-asserted-by":"publisher","first-page":"20685","DOI":"10.1200\/jco.2008.26.15suppl.20685","article-title":"Hand-foot syndrome: symptom assessment and the impact on quality of life\u2014a review of the peer-reviewed literature","volume":"26","author":"Keating","year":"2008","journal-title":"J Clin Oncol"},{"key":"2026071005213761900_oyag233-B12","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1634\/theoncologist.2014-0219","article-title":"The hand-foot skin reaction and quality of life questionnaire: an assessment tool for oncology","volume":"20","author":"Anderson","year":"2015","journal-title":"J Oncol"},{"key":"2026071005213761900_oyag233-B13","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1634\/theoncologist.2008-0237","article-title":"Search for evidence-based approaches for the prevention and palliation of hand\u2013foot skin reaction (HFSR) caused by the multikinase inhibitors (MKIs)","volume":"14","author":"Anderson","year":"2009","journal-title":"J Oncol"},{"key":"2026071005213761900_oyag233-B14","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1007\/s00520-010-0851-8","article-title":"Skin care management in cancer patients: an evaluation of quality of life and tolerability","volume":"19","author":"Haley","year":"2011","journal-title":"Support Care Cancer"},{"key":"2026071005213761900_oyag233-B15","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1093\/annonc\/mdg446","article-title":"High incidence of severe hand\u2013foot syndrome during capecitabine\u2013docetaxel combination chemotherapy","volume":"14","author":"Park","year":"2003","journal-title":"Ann Oncol"},{"key":"2026071005213761900_oyag233-B16","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.6004\/jnccn.2009.0074","article-title":"NCCN task force report: management of dermatologic and other toxicities associated with EGFR inhibition in patients with cancer","volume":"7 Suppl 1","author":"Burtness","year":"2009","journal-title":"J Natl Compr Canc Netw"},{"key":"2026071005213761900_oyag233-B17","doi-asserted-by":"publisher","first-page":"442","DOI":"10.4081\/oncol.2020.442","article-title":"Management of cytotoxic chemotherapy-induced hand-foot syndrome","volume":"14","author":"Kwakman","year":"2020","journal-title":"Oncol Rev"},{"key":"2026071005213761900_oyag233-B18","doi-asserted-by":"publisher","first-page":"5182","DOI":"10.1200\/JCO.2010.31.143","article-title":"Placebo-controlled trial to determine the effectiveness of a urea\/lactic acid\u2013based topical keratolytic agent for prevention of capecitabine-induced hand-foot syndrome: North Central cancer treatment group study N05C5","volume":"28","author":"Wolf","year":"2010","journal-title":"J Clin Oncol"},{"key":"2026071005213761900_oyag233-B19","doi-asserted-by":"publisher","first-page":"873","DOI":"10.3892\/br.2013.161","article-title":"Prophylactic pyridoxine was not able to reduce the incidence of capecitabine-induced hand-foot syndrome: a meta-analysis","volume":"1","author":"Zhou","year":"2013","journal-title":"Biomed Rep"},{"key":"2026071005213761900_oyag233-B20","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1200\/JCO.2013.52.9651","article-title":"Randomized controlled trial of the prophylactic effect of urea-based cream on sorafenib-associated hand-foot skin reactions in patients with advanced hepatocellular carcinoma","volume":"33","author":"Ren","year":"2015","journal-title":"J Clin Oncol"},{"key":"2026071005213761900_oyag233-B21","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1016\/j.jaad.2014.03.019","article-title":"Chemotherapy-induced hand-foot syndrome and nail changes: a review of clinical presentation, etiology, pathogenesis, and management","volume":"71","author":"Miller","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"2026071005213761900_oyag233-B22","doi-asserted-by":"publisher","first-page":"401","DOI":"10.2147\/CMAR.S52256","article-title":"Daily baseline skin care in the prevention, treatment, and supportive care of skin toxicity in oncology patients: recommendations from a multinational expert panel","volume":"5","author":"Bensadoun","year":"2013","journal-title":"Cancer Manag Res"},{"key":"2026071005213761900_oyag233-B23","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.ejca.2008.01.028","article-title":"Pegylated liposomal doxorubicin-associated hand\u2013foot syndrome: recommendations of an international panel of experts","volume":"44","author":"von Moos","year":"2008","journal-title":"Eur J Cancer"},{"key":"2026071005213761900_oyag233-B24","doi-asserted-by":"publisher","first-page":"4735","DOI":"10.1002\/cncr.25262","article-title":"A double-blind, randomized trial of pyridoxine versus placebo for the prevention of pegylated liposomal doxorubicin-related hand-foot syndrome in gynecologic oncology patients","volume":"116","author":"von Gruenigen","year":"2010","journal-title":"Cancer"},{"key":"2026071005213761900_oyag233-B25","doi-asserted-by":"publisher","first-page":"S31","DOI":"10.1016\/j.ejon.2004.06.007","article-title":"Management of hand-foot syndrome in patients treated with capecitabine (xeloda\u00ae)","volume":"8 Suppl 1","author":"Lassere","year":"2004","journal-title":"Eur J Oncol Nurs"},{"key":"2026071005213761900_oyag233-B26","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1007\/s13555-022-00685-2","article-title":"An emollient plus balm is useful for the management of xerosis in patients treated for cancer: a real-world, prospective, observational, multicenter study","volume":"12","author":"Vendrely","year":"2022","journal-title":"Dermatol Ther"},{"key":"2026071005213761900_oyag233-B27","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1007\/s11136-019-02133-9","article-title":"A pilot study on aesthetic treatments performed by qualified aesthetic practitioners: efficacy on health-related quality of life in breast cancer patients","volume":"28","author":"Oliveri","year":"2019","journal-title":"Qual Life Res"},{"key":"2026071005213761900_oyag233-B28"},{"key":"2026071005213761900_oyag233-B29","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.jaad.2006.03.036","article-title":"Instrumental assessment of atopic eczema: validation of transepidermal water loss, stratum corneum hydration, erythema, scaling, and edema","volume":"55","author":"Holm","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"2026071005213761900_oyag233-B30","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1098\/rsif.2008.0034","article-title":"Influence of epidermal hydration on the friction of human skin against textiles","volume":"5","author":"Gerhardt","year":"2008","journal-title":"J R Soc Interface"},{"key":"2026071005213761900_oyag233-B31","first-page":"123","volume-title":"Practical Aspects of Cosmetic Testing: How to Set up a Scientific Study in Skin Physiology","author":"Darlenski","year":"2010"},{"key":"2026071005213761900_oyag233-B32","author":"Courage and Khazaka Electronic GmbH"},{"key":"2026071005213761900_oyag233-B33","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1111\/j.1600-0846.2007.00256.x","article-title":"Derivation and clinical application of special imaging by means of digital cameras and image J freeware for quantification of erythema and pigmentation","volume":"14","author":"Yamamoto","year":"2008","journal-title":"Skin Res Technol"},{"key":"2026071005213761900_oyag233-B34","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1034\/j.1600-0846.2000.006004230.x","article-title":"Skin color measurements: comparison between three instruments: the chromameter\u00ae, the DermaSpectrometer\u00ae and the mexameter\u00ae","volume":"6","author":"Clarys","year":"2000","journal-title":"Skin Res Technol"},{"key":"2026071005213761900_oyag233-B35","author":"Courage and Khazaka Electronic GmbH"},{"key":"2026071005213761900_oyag233-B36","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.det.2011.11.003","article-title":"The Skindex instruments to measure the effects of skin disease on quality of life","volume":"30","author":"Chren","year":"2012","journal-title":"Dermatol Clin"},{"key":"2026071005213761900_oyag233-B37","doi-asserted-by":"publisher","first-page":"1955","DOI":"10.1093\/annonc\/mdn389","article-title":"Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib","volume":"19","author":"Lacouture","year":"2008","journal-title":"Ann Oncol"},{"key":"2026071005213761900_oyag233-B38","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/BF02737863","article-title":"Measurement properties of Skindex-16: a brief quality-of-life measure for patients with skin diseases","volume":"5","author":"Chren","year":"2001","journal-title":"J Cutan Med Surg"},{"key":"2026071005213761900_oyag233-B39","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/1748-717X-8-57","article-title":"Preventing the acute skin side effects in patients treated with radiotherapy for breast cancer: the use of corneometry in order to evaluate the protective effect of moisturizing creams","volume":"8","author":"Di Franco","year":"2013","journal-title":"Radiat Oncol"},{"key":"2026071005213761900_oyag233-B40","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1517\/14740338.2011.546342","article-title":"Capecitabine and hand\u2013foot syndrome","volume":"10","author":"Saif","year":"2011","journal-title":"Expert Opin Drug Saf"},{"key":"2026071005213761900_oyag233-B41","doi-asserted-by":"publisher","first-page":"65","DOI":"10.12788\/jcso.0017","article-title":"Randomized trial of vitamin B6 for preventing hand-foot syndrome from capecitabine chemotherapy","volume":"12","author":"Braik","year":"2014","journal-title":"J Community Support Oncol"},{"key":"2026071005213761900_oyag233-B42","doi-asserted-by":"publisher","first-page":"3824","DOI":"10.1200\/JCO.2010.29.1807","article-title":"Pyridoxine is not effective to prevent hand-foot syndrome associated with capecitabine therapy: results of a randomized, double-blind, placebo-controlled study","volume":"28","author":"Kang","year":"2010","journal-title":"J Clin Oncol"},{"key":"2026071005213761900_oyag233-B43","doi-asserted-by":"publisher","first-page":"e1532","DOI":"10.1002\/cnr2.1532","article-title":"Validation of the prophylactic efficacy of urea-based creams on sorafenib-induced hand-foot skin reaction in patients with advanced hepatocellular carcinoma: a randomised experiment study","volume":"5","author":"Lien","year":"2022","journal-title":"Cancer Rep"},{"key":"2026071005213761900_oyag233-B44","doi-asserted-by":"publisher","first-page":"2444","DOI":"10.1200\/JCO.2014.60.4587","article-title":"Mapisal versus urea cream as prophylaxis for capecitabine-associated hand-foot syndrome: a randomized phase III trial of the AIO quality of life working group","volume":"33","author":"Hofheinz","year":"2015","journal-title":"J Clin Oncol"},{"key":"2026071005213761900_oyag233-B45","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1081\/cnv-120000360","article-title":"Incidence and severity of hand\u2013foot syndrome in colorectal cancer patients treated with capecitabine: a single-institution experience","volume":"20","author":"Abushullaih","year":"2002","journal-title":"Cancer Invest"},{"key":"2026071005213761900_oyag233-B46","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1111\/j.1346-8138.2010.01059.x","article-title":"Sorafenib-associated hand\u2013foot syndrome in Japanese patients","volume":"38","author":"Iijima","year":"2011","journal-title":"J Dermatol"},{"key":"2026071005213761900_oyag233-B47","doi-asserted-by":"publisher","first-page":"4846","DOI":"10.7150\/jca.31059","article-title":"Hand foot syndrome has the strongest impact on QOL in skin toxicities of chemotherapy","volume":"10","author":"Urakawa","year":"2019","journal-title":"J Cancer"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag233\/68520400\/oyag233.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/8\/oyag233\/68520400\/oyag233.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/8\/oyag233\/68520400\/oyag233.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T09:21:44Z","timestamp":1783675304000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag233\/8707345"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,12]]},"references-count":47,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,7,8]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag233","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8]]},"published":{"date-parts":[[2026,6,12]]},"article-number":"oyag233"}}